MDACC Study No:2010-0907 ( NCT No: NCT01400503)
Title:An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Subjects with Multicentric Castleman’s Disease
Principal Investigator:Luis E. Fayad
Treatment Agent:CNTO 328
Study Status:Closed
Study Description:The goal of this clinical research study is to learn more about the long term
safety of siltuximab in patients with multicentric Castleman's disease.
Researchers also want to learn if siltuximab can help to control multicentric
Castleman's disease.

Siltuximab is an antibody that is designed to block the activity of IL-6 (a
protein found naturally in the body that can promote the growth of cancer
cells). By blocking IL-6, siltuximab may slow cancer growth.
Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:CNTO 328
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Janssen Research & Development, LLC
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Luis E. Fayad
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults